Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells

Clinical and Experimental Metastasis

Volumn 28, Issue 4, 2011, Pages 367-376

  Kobayashi, Tsutomu ^a   Shimura, Tatsuo ^a,b   Yajima, Toshiki ^a   Kubo, Norio ^a   Araki, Kenichiro ^a   Wada, Wataru ^a   Tsutsumi, Soichi ^a   Suzuki, Hideki ^a   Kuwano, Hiroyuki ^a   Raz, Avraham ^c  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; Apoptosis; Galectin 3; Gemcitabine; Pancreatic cancer

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; GALECTIN 3; GEMCITABINE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GALECTIN 3; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; RNA INTERFERENCE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 79955522603     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-011-9376-x     Document Type: Article

References (43)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 19474385 10.3322/caac.20006
2. H Ueno T Kosuge Y Matsuyama, et al. 2009 A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer Br J Cancer 101 908 915 19690548 10.1038/sj.bjc.6605256 1:CAS:528:DC%2BD1MXhtV2qsrjN
3. WF Regine KA Winter RA Abrams, et al. 2008 Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial Jama 299 1019 1026 18319412 10.1001/jama.299.9.1019 1:CAS:528:DC%2BD1cXjtVSltL0%3D (Pubitemid 351347058)
4. H Oettle S Post P Neuhaus, et al. 2007 Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial Jama 297 267 277 17227978 10.1001/jama.297.3.267 1:CAS:528:DC%2BD2sXotVCmug%3D%3D (Pubitemid 46143304)
5. HA Burris III MJ Moore J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
6. TS Lawrence MA Davis A Hough, et al. 2001 The role of apoptosis in 2′, 2′-difluoro-2′-deoxycytidine (gemcitabine)-mediated radiosensitization Clin Cancer Res 7 314 319 11234886 1:CAS:528: DC%2BD3MXhvFKnsb4%3D (Pubitemid 32183035)
7. SH Barondes V Castronovo DN Cooper, et al. 1994 Galectins: a family of animal beta-galactoside-binding lectins Cell 76 597 598 8124704 10.1016/0092-8674(94)90498-7 1:CAS:528:DyaK2cXitlymur8%3D (Pubitemid 24070645)
8. SH Barondes DN Cooper MA Gitt, et al. 1994 Galectins. Structure and function of a large family of animal lectins J Biol Chem 269 20807 20810 8063692 1:CAS:528:DyaK2cXlsFWgurc%3D
9. CA Gray DL Adelson FW Bazer, et al. 2004 Discovery and characterization of an epithelial-specific galectin in the endometrium that forms crystals in the trophectoderm Proc Natl Acad Sci U S A 101 7982 7987 15148380 10.1073/pnas.0402669101 1:CAS:528:DC%2BD2cXkslCisLg%3D (Pubitemid 38698040)
10. DK Hsu AI Chernyavsky HY Chen, et al. 2009 Endogenous galectin-3 is localized in membrane lipid rafts and regulates migration of dendritic cells J Invest Dermatol 129 573 583 18843294 10.1038/jid.2008.276 1:CAS:528: DC%2BD1MXhslShsb0%3D
11. P Nangia-Makker S Nakahara V Hogan, et al. 2007 Galectin-3 in apoptosis, a novel therapeutic target J Bioenerg Biomembr 39 79 84 17318396 10.1007/s10863-006-9063-9 1:CAS:528:DC%2BD2sXmtFent7s%3D (Pubitemid 46877176)
12. S Akahani P Nangia-Makker H Inohara, et al. 1997 Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family Cancer Res 57 5272 5276 9393748 1:CAS:528:DyaK2sXnslGru7w%3D (Pubitemid 27516362)
13. T Fukumori HO Kanayama A Raz 2007 The role of galectin-3 in cancer drug resistance Drug Resist Updat 10 101 108 17544840 10.1016/j.drup.2007.04.001 1:CAS:528:DC%2BD2sXnslWksr8%3D (Pubitemid 47031053)
14. N Mazurek YJ Sun KF Liu, et al. 2007 Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells J Biol Chem 282 21337 21348 17420249 10.1074/jbc.M608810200 1:CAS:528:DC%2BD2sXns1ynsbc%3D (Pubitemid 47099965)
15. T Fukumori N Oka Y Takenaka, et al. 2006 Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer Cancer Res 66 3114 3119 16540661 10.1158/0008-5472.CAN- 05-3750 1:CAS:528:DC%2BD28Xitlertr0%3D
16. J Fukushi IT Makagiansar WB Stallcup, et al. 2004 NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin Mol Biol Cell 15 3580 3590 15181153 10.1091/mbc.E04-03-0236 1:CAS:528:DC%2BD2cXms1GgtLw%3D (Pubitemid 38989698)
17. A Raz L Meromsky R Lotan 1986 Differential expression of endogenous lectins on the surface of nontumorigenic, tumorigenic, and metastatic cells Cancer Res 46 3667 3672 3518919 1:CAS:528:DyaL28XksFyku7s%3D (Pubitemid 16096926)
18. J Ochieng R Fridman P Nangia-Makker, et al. 1994 Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9 Biochemistry 33 14109 14114 7947821 10.1021/bi00251a020 1:CAS:528:DyaK2cXmvFGkurY%3D (Pubitemid 24382354)
19. HC Gong Y Honjo P Nangia-Makker, et al. 1999 The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells Cancer Res 59 6239 6245 10626818 1:CAS:528:DC%2BD3cXktFyguw%3D%3D (Pubitemid 30035648)
20. HR Kim HM Lin H Biliran, et al. 1999 Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells Cancer Res 59 4148 4154 10463621 1:CAS:528:DyaK1MXlsVOlu7w%3D (Pubitemid 29393591)
21. HM Lin BK Moon F Yu, et al. 2000 Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis Carcinogenesis 21 1941 1945 11062152 10.1093/carcin/21.11.1941 1:CAS:528:DC%2BD3cXoslWqsbg%3D
22. H Sano DK Hsu JR Apgar, et al. 2003 Critical role of galectin-3 in phagocytosis by macrophages J Clin Invest 112 389 397 12897206 1:CAS:528:DC%2BD3sXmtFemtrw%3D (Pubitemid 38063767)
23. RY Yang DK Hsu FT Liu 1996 Expression of galectin-3 modulates T-cell growth and apoptosis Proc Natl Acad Sci U S A 93 6737 6742 8692888 10.1073/pnas.93.13.6737 1:CAS:528:DyaK28XjvFeisbk%3D (Pubitemid 26230379)
24. Y Takenaka T Fukumori T Yoshii, et al. 2004 Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs Mol Cell Biol 24 4395 4406 15121858 10.1128/MCB.24.10. 4395-4406.2004 1:CAS:528:DC%2BD2cXjvFChtLY%3D (Pubitemid 41071009)
25. P Matarrese N Tinari ML Semeraro, et al. 2000 Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis FEBS Lett 473 311 315 10818231 10.1016/S0014-5793(00)01547-7 1:CAS:528:DC%2BD3cXjt1eju7k%3D (Pubitemid 30249145)
26. P Matarrese O Fusco N Tinari, et al. 2000 Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties Int J Cancer 85 545 554 10699929 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0. CO;2-N 1:CAS:528:DC%2BD3cXht1amt74%3D (Pubitemid 30075135)
27. SR Datta A Brunet ME Greenberg 1999 Cellular survival: a play in three Akts Genes Dev 13 2905 2927 10579998 10.1101/gad.13.22.2905 1:CAS:528: DyaK1MXnvVCltLo%3D
28. N Oka S Nakahara Y Takenaka, et al. 2005 Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells Cancer Res 65 7546 7553 16140916 1:CAS:528:DC%2BD2MXpslait7c%3D (Pubitemid 41297223)
29. VM Bondar B Sweeney-Gotsch M Andreeff, et al. 2002 Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo Mol Cancer Ther 1 989 997 12481421 1:CAS:528:DC%2BD3sXmtFaguw%3D%3D
30. P Dumont A Berton N Nagy, et al. 2008 Expression of galectin-3 in the tumor immune response in colon cancer Lab Invest 88 896 906 18542048 10.1038/labinvest.2008.54 1:CAS:528:DC%2BD1cXovV2lt7Y%3D
31. AA Mourad-Zeidan VO Melnikova H Wang, et al. 2008 Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry Am J Pathol 173 1839 1852 18988806 10.2353/ajpath.2008.080380 1:CAS:528:DC%2BD1MXkt1CqtQ%3D%3D
32. Y Wang P Nangia-Makker L Tait, et al. 2009 Regulation of prostate cancer progression by galectin-3 Am J Pathol 174 1515 1523 19286570 10.2353/ajpath.2009.080816 1:CAS:528:DC%2BD1MXksVOku7Y%3D
33. HB Jiang M Xu XP Wang 2008 Pancreatic stellate cells promote proliferation and invasiveness of human pancreatic cancer cells via galectin-3 World J Gastroenterol 14 2023 2028 18395901 10.3748/wjg.14.2023 1:CAS:528:DC%2BD1cXnvFShtbg%3D (Pubitemid 351795821)
34. R Levy M Grafi-Cohen Z Kraiem, et al. 2010 Galectin-3 promotes chronic activation of k-ras and differentiation block in malignant thyroid carcinomas Mol Cancer Ther 9 2208 2219 20682656 10.1158/1535-7163.MCT-10-0262 1:CAS:528:DC%2BC3cXpvVOjs7w%3D
35. P Nangia-Makker T Raz L Tait, et al. 2007 Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers Cancer Res 67 11760 11768 18089806 10.1158/0008-5472.CAN-07-3233 1:CAS:528:DC%2BD2sXhsVCjs7jM
36. MH Cardone N Roy HR Stennicke, et al. 1998 Regulation of cell death protease caspase-9 by phosphorylation Science 282 1318 1321 9812896 10.1126/science.282.5392.1318 1:CAS:528:DyaK1cXnsFentLY%3D (Pubitemid 28524494)
37. SR Datta H Dudek X Tao, et al. 1997 Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91 231 241 9346240 10.1016/S0092-8674(00)80405-5 1:CAS:528:DyaK2sXntVyiu7k%3D (Pubitemid 27456390)
38. L del Peso M Gonzalez-Garcia C Page, et al. 1997 Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt Science 278 687 689 9381178 10.1126/science.278.5338.687 1:CAS:528:DyaK2sXmvVyns7o%3D (Pubitemid 27464966)
39. RG Jones M Parsons M Bonnard, et al. 2000 Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo J Exp Med 191 1721 1734 10811865 10.1084/jem.191.10.1721 1:CAS:528:DC%2BD3cXjtlKgurc%3D (Pubitemid 30331569)
40. T Mashima T Tsuruo 2005 Defects of the apoptotic pathway as therapeutic target against cancer Drug Resist Updat 8 339 343 16338161 10.1016/j.drup.2005. 11.001 1:CAS:528:DC%2BD28Xit1Cku7w%3D (Pubitemid 43358057)
41. S Desagher JC Martinou 2000 Mitochondria as the central control point of apoptosis Trends Cell Biol 10 369 377 10932094 10.1016/S0962-8924(00)01803-1 1:CAS:528:DC%2BD3cXls1CktLk%3D (Pubitemid 30612469)
42. LC Cantley BG Neel 1999 New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proc Natl Acad Sci U S A 96 4240 4245 10200246 10.1073/pnas.96.8.4240 1:CAS:528:DyaK1MXjs1ymtbg%3D (Pubitemid 29190320)
43. X Wan LJ Helman 2003 Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells Oncogene 22 8205 8211 14603261 10.1038/sj.onc.1206878 1:CAS:528:DC%2BD3sXoslSis7s%3D (Pubitemid 37487311)